[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100508226":3},{"organization":4,"outcomesModule":7,"designInfo":53,"detailedDescription":16,"studyPopulation":16,"armGroups":64,"interventions":77,"overallOfficials":16,"centralContacts":85,"locations":16,"responsibleParty":95,"collaborators":97,"id":100,"slug":16,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":101,"sex":107,"minAge":108,"maxAge":16,"enrollmentInfo":109,"targetDuration":16,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":16,"overallStatus":119,"whyStopped":16,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":16},{"fullName":5,"class":6},"Hamilton Health Sciences Corporation","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":37},[9],{"measure":10,"description":11,"timeFrame":12},"Recruitment Rate","Feasibility outcome","Through study completion, approximately 1 year",[14,17,19,22,25,27,29,31,34],{"measure":15,"description":16,"timeFrame":12},"Fraction of eligible patients approached",null,{"measure":18,"description":16,"timeFrame":12},"Fraction of approached patients consent",{"measure":20,"description":21,"timeFrame":12},"Role of individual who approached patients","Description of research team member first approaching and consenting patients (e.g. resident, research staff, staff surgeon, etc.)",{"measure":23,"description":24,"timeFrame":12},"Protocol adherence","Number of participants who withdrawal from the study",{"measure":23,"description":26,"timeFrame":12},"Drug adherence rate",{"measure":23,"description":28,"timeFrame":12},"Follow-up completion rate",{"measure":23,"description":30,"timeFrame":12},"Method of follow-up (e.g. telephone, clinic visit)",{"measure":32,"description":33,"timeFrame":12},"Adverse events","Serious and related adverse events and adverse drug reactions",{"measure":35,"description":36,"timeFrame":12},"Unblinding events","Number of events and reasoning",[38,41,44,46,49,51],{"measure":39,"description":16,"timeFrame":40},"New onset seizure within 7 days of surgery","7 days post-surgery, reviewed at follow-up between post-operative day 8 and 14",{"measure":42,"description":16,"timeFrame":43},"Incidence of infection during Study Drug administration","Follow-up between post-operative day 8 and 14",{"measure":45,"description":16,"timeFrame":43},"Incidence of psychiatric symptoms during Study Drug Administration",{"measure":47,"description":16,"timeFrame":48},"Length of hospital stay in days","Hospital discharge",{"measure":50,"description":16,"timeFrame":43},"Incidence of administration of any antiepileptic drugs",{"measure":52,"description":16,"timeFrame":43},"Incidence of administration of any benzodiazepines",{"allocation":54,"interventionModel":55,"interventionModelDescription":16,"primaryPurpose":56,"observationalModel":16,"timePerspective":16,"maskingInfo":57},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":58,"maskingDescription":16,"whoMasked":59},"QUADRUPLE",[60,61,62,63],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[65,71],{"label":66,"type":67,"description":68,"interventionNames":69},"Seizure Prophylaxis (Levetiracetam)","EXPERIMENTAL","Levetiracetam 1 g taken orally twice a day for 7 days",[70],"Drug: Levetiracetam",{"label":72,"type":73,"description":74,"interventionNames":75},"Placebo","PLACEBO_COMPARATOR","Placebo taken orally twice a day for 7 days",[76],"Other: Placebo",[78,83],{"type":79,"name":80,"description":81,"armGroupLabels":82,"otherNames":16},"DRUG","Levetiracetam","Tablets",[66],{"type":6,"name":72,"description":81,"armGroupLabels":84,"otherNames":16},[72],[86,92],{"name":87,"role":88,"phone":89,"phoneExt":90,"email":91},"Taylor Duda, MD","CONTACT","905-521-2100","44155","taylor.duda@medportal.ca",{"name":93,"role":88,"phone":89,"phoneExt":90,"email":94},"Amanda Martyniuk, MSc","martynia@mcmaster.ca",{"type":96,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR",[98],{"name":99,"class":6},"McMaster University","100508226",false,"NCT05897658","Levetiracetam Prophylaxis in Brain Tumor Resection Pilot","Pilot Study: Levetiracetam Prophylaxis Randomized Controlled Trial in Brain Tumor Resection","LeviTaTe Pilot","Inclusion Criteria:\n\n* Adult age 18 years or older\n* Undergoing craniotomy for a brain tumor\n* Intra-axial tumor location\n* Supratentorial tumor location\n\nExclusion Criteria:\n\n* Documented seizure history or epilepsy diagnosis\n* Currently taking an antiepileptic medication\n* Unable to take levetiracetam (e.g. allergy, inability to swallow)\n* Inability to obtain consent from participant or substitute decision maker prior to surgery\n* Renal impairment with eGFR less than 50\n* Pregnancy","ALL","18 Years",{"count":110,"type":111},70,"ESTIMATED","INTERVENTIONAL",[114],"PHASE3","This study aims to evaluate feasibility of a double-blind randomized controlled trial for levetiracetam prophylaxis for prevention of seizure in the perioperative phase of brain tumor resection.",[117,118],"Seizures","Brain Tumor","NOT_YET_RECRUITING","2024-10-21",{"date":122,"type":123},"2024-10-23","ACTUAL",{"date":125,"type":111},"2025-03",{"date":127,"type":111},"2026-03",{"name":5,"class":6}]